Myeloproliferative Neoplasms (MPN)

CNL/atypical CML
- IRB#10262: Oral Ruxolitinib for CNL or atypical CML.

Myelofibrosis
- IRB#16363: Phase 2 INC8050465 plus Ruxolitinib
- IRB#15836: Dual Syk/Jak inhibitor for myelofibrosis with JAK2 mutation

Systemic Mastocytosis
- IRB#15977: Non Treatment National MDS Study (ECOG/ACRIN)

IRB#17899: Study Coming Soon

http://www.ohsu.edu/research/rda/so/knight.php